SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
AIM

AIM ImmunoTech Inc. (New York Stock Exchange Arca:AIM)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.11-$0.01 (-4.50%)
 
Market cap
$4.57M
Insider Score
Health Score
Analyst consensus
Listed since
Nov 2, 1995
Market Cap$4.57M-91.6%
Revenue (ttm)$91.00K-18.8%
Net Income-$14.13M+10.3%
EPS-$0.35+70.2%
Shares Out39.92M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,244,557
Open$0.12
Previous Close$0.12
Day's Range$0.11 - $0.13
52-Week Range$0.11 - $1.88
Beta1.31
AnalystsBuy
Price Targetn/a
Earnings DateMar 26, 2027

About AIM

AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.

Address
2117 SW Highway 484, Ocala, FL, 34473, US
Market Cap
5 million
Employees
19
Industrial Classification
Biotechnology

AIM ImmunoTech Inc. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
47th Percentile Overall Score
AIM InsiderScore:66 / 99

AIM ImmunoTech Inc. scored higher than 47% of companies evaluated by InsiderBuying, and ranked 44th out of 110 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at AIM ImmunoTech Inc. bought $58.8K of stock across 14 purchases in the last 90 days, the largest of them $6.5K.

Stake Increase

The average purchase added about 13% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

Every buyer already held stock, so each purchase is an increase rather than a first position.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$58.83K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Fair
From AIM’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-4.50%
5 Days
-20.97%
1 Month
-32.59%
6 Months
-52.94%
1 Year
-91.64%

$AIM stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in AIM holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by AIM's directors and management

Net Shares Purchased by Insiders−400k−200k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

AIM Estimated quarterly lobbying spending

Source: U.S. Senate LDA

AIM Revenue by Segment or Geography

AIM's latest filing doesn't break out revenue by segment.

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New AIM patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to AIM from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from AIM’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
60.89
Analyst Ratings
32% of score
60
News & Sentiment
20% of score
72

News check: Major clinical catalysts expected (pancreatic cancer Phase 2 data Q1 2027) combined with routine corporate updates support moderately bullish sentiment.

Recent Insider Activity

Buys
14
Sells
0
Buy Value
$58.83K
Distinct Buyers
1

Insider Score Trend Over Time

+10.6 since Sep 24
0255075100Sep 24 — Insider Score 55.2Sep 25 — Insider Score 61.0Sep 26 — Insider Score 60.8Sep 27 — Insider Score 60.8Sep 28 — Insider Score 60.9Sep 29 — Insider Score 60.5Sep 30 — Insider Score 60.2Oct 1 — Insider Score 60.0Oct 2 — Insider Score 32.0Oct 3 — Insider Score 59.7Oct 4 — Insider Score 59.7Oct 5 — Insider Score 59.7Oct 6 — Insider Score 59.5Oct 7 — Insider Score 59.3Oct 8 — Insider Score 59.1Oct 9 — Insider Score 58.9Oct 10 — Insider Score 58.7Oct 11 — Insider Score 59.1Oct 12 — Insider Score 59.0Oct 13 — Insider Score 58.8Oct 14 — Insider Score 58.4Oct 15 — Insider Score 58.4Oct 16 — Insider Score 58.4Oct 17 — Insider Score 58.3Oct 18 — Insider Score 58.4Oct 19 — Insider Score 58.3Oct 20 — Insider Score 58.2Oct 21 — Insider Score 58.0Oct 22 — Insider Score 58.0Oct 23 — Insider Score 57.9Oct 24 — Insider Score 57.9Oct 25 — Insider Score 62.4Oct 26 — Insider Score 64.7Oct 27 — Insider Score 64.7Oct 28 — Insider Score 64.7Oct 29 — Insider Score 64.5Oct 30 — Insider Score 63.9Oct 31 — Insider Score 63.9Nov 1 — Insider Score 63.9Nov 2 — Insider Score 63.8Nov 3 — Insider Score 63.6Nov 4 — Insider Score 63.3Nov 5 — Insider Score 62.9Nov 6 — Insider Score 62.4Nov 7 — Insider Score 63.8Nov 8 — Insider Score 63.9Nov 9 — Insider Score 63.9Nov 10 — Insider Score 66.2Nov 11 — Insider Score 66.0Nov 12 — Insider Score 66.3Nov 13 — Insider Score 66.4Nov 14 — Insider Score 66.1Nov 15 — Insider Score 66.1Nov 16 — Insider Score 65.9Nov 17 — Insider Score 65.3Nov 18 — Insider Score 65.8Nov 19 — Insider Score 66.2Nov 20 — Insider Score 66.2Nov 21 — Insider Score 65.9Nov 22 — Insider Score 65.9Sep 24Oct 23Nov 22

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.